Vascular endothelial growth factor (VEGF) prolongs survival in the mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS), whereas dysregulation of VEGF through deletion of its hypoxia-regulatory element causes motor neuron degeneration in mice. We investigated the expression of VEGF and its major agonist receptors in the normal central nervous system and in patients with ALS. Immunohistochemistry demonstrated similar expression patterns of VEGF and VEGF receptor 2 (VEGFR2) in the spinal cord with finely punctate staining of the neuropil and strong expression in anterior horn cells (AHCs). Granular staining on the surface of some AHCs, similar to that seen with synaptic markers, suggested synaptic labeling. VEGFR2 staining was reduced in the neuropil of ALS cases (p = 0.018) associated with a reduction of synaptophysin but not SNAP25 expression. A greater proportion of AHCs in ALS cases showed low expression of VEGF (p = 0.006) and VEGFR2 (p = 0.009) compared with controls. Expression of VEGF and VEGFR2 was confirmed by Western blotting and quantitative reverse transcriptase-polymerase chain reaction (QPCR). The similar expression patterns of VEGF and VEGFR2 suggests autocrine/ paracrine effects on spinal motor neurons, and the reduction in their expression seen in ALS cases would support the hypothesis that, as in mouse models of the disease, reduced VEGF signaling may play a role in the pathogenesis of ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative condition characterized by cell injury and death of upper motor neurons in the cerebral cortex and lower motor neurons in the brainstem and spinal cord. In 10% of cases, the disease is familial, and one fifth of these cases are caused by mutations in Cu/Zn superoxide dismutase (SOD1), which result in a toxic gain of function of the mutant protein.
Other mutations have been identified in small numbers of patients, including the neurofilament heavy subunit (1), dynactin I (2), alsin, a putative GTPase regulator (3, 4) , senataxin, a putative RNA/DNA helicase (5) , and the vesicletrafficking protein VAPB (6) . However, in the majority of familial disease, and in patients with sporadic ALS, the cause of selective degeneration of motor neurons has not been established with certainty. A number of pathogenic mechanisms are thought to be involved in the degenerative process, including oxidative stress, excitotoxicity, inflammation, mitochondrial and neurofilament dysfunction, and ultimately activation of a programmed cell death pathway (7, 8) .
Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen essential for angiogenesis in embryologic development and involved in several pathologic conditions such as tumor growth and diabetic retinopathy (9) . The expression of VEGF is upregulated by hypoxia, a response mediated by binding of hypoxia-inducible factor (HIF-1) to a hypoxia-regulatory element in the 5' promoter (10, 11) . VEGF binds 2 related receptor tyrosine kinases: VEGFR1 (or Flt-1) and VEGFR2 (also known as KDR or Flk-1). A third receptor in this family, VEGFR3 (Flt-4), is not a receptor for VEGF but binds its homologs VEGFC and VEGFD. VEGFR2 is the major mediator of mitogenic and angiogenic effects of VEGF. VEGFR1 binds VEGF with high affinity, and although functional VEGFR1 signaling occurs within certain cell types, its major function appears to be that of a ''decoy receptor'' that negatively regulates VEGF function by preventing binding to VEGFR2. VEGF also binds a family of coreceptors, the neuropilins (NRPs), which were originally described as receptors for the semaphorin family, mediating neuronal cell guidance (9) .
In 2001, Oosthuyse et al found that deletion of the hypoxia-regulatory element of VEGF in mice unexpectedly caused adult-onset motor neuron degeneration with clinical and neuropathologic features reminiscent of ALS (12) . Both baseline levels and hypoxic induction of VEGF are reduced in the neural tissue of these VEGF d/d mice. The mechanism underlying their phenotype is not certain. They have abnormalities of baseline spinal cord blood flow, suggesting that chronic ischemia may underlie late-onset neurodegeneration. Alternatively, VEGF acts as a neurotrophic factor in vitro and in vivo, and motor neuron loss in VEGF d/d mice may be the result of inadequate neurotrophic support (12, 13) .
Animal studies suggest that VEGF is an important determinant of motor neuron survival and that dysregulation of VEGF can cause motor neuron degeneration. The relevance of these findings in animal models to the human disease is uncertain. There is evidence from human genetic studies that low expression of VEGF is a risk factor for the development of ALS (13), although not all studies have confirmed the association initially described (14) . We hypothesize that VEGF has a neurotrophic action in the human central nervous system (CNS) and that disruption of the VEGF-signaling pathway may be an etiologic factor in human motor neuron degeneration (15) . In this study, we have characterized the patterns and levels of expression of VEGF and its receptors in the normal CNS and determined whether this expression is altered in patients with ALS using immunohistochemistry, quantitative reverse transcriptase-polymerase chain reaction (QPCR), and Western blotting.
MATERIALS AND METHODS

Case Selection
Blocks of cervical and lumbar spinal cord, hippocampus, and frontal cortex were obtained from 10 cases of ALS from the Sheffield CNS tissue bank. Ten control cases were selected for spinal cord studies, and 4 for frontal and hippocampal studies, with no history of motor neuron disorder or spinal cord pathology (Table 1) . Frozen spinal cord tissue from the same population of patients with ALS and control cases was used for Western blotting and quantitative PCR. Tissue donated for research was obtained with informed consent from the next of kin and in accordance with the Medical Research Council guidelines on tissue donation. Approval for the study was obtained from the local research ethics committee. 
Immunohistochemistry
Immunohistochemistry was performed with antibodies to VEGF (using 2 different antibodies) and its agonist receptors VEGFR2 and NRP1 using an ABC method and the signal visualized with diaminobenzidine. The pattern of synaptic staining was demonstrated with antibodies to synaptophysin and SNAP-25. Immunohistochemistry to ubiquitin was performed on the hippocampal and cord blocks from the ALS cases. Primary antibodies were used as detailed in Table 2 . Omission of primary antibody was used as a negative control for each antibody. In addition, rabbit IgG was used as an isotype control, diluted for application at a similar protein concentration to that of the specific antibodies. In a separate, additional set from the cervical cord blocks from all of the cases, serial sections were immunostained for ubiquitin, VEGFR2, and SNAP25.
Immunohistochemical staining was assessed by a neuropathologist (SBW). Staining was noted in glia and in the vasculature. The intensity of staining in anterior and posterior horn neuropil and in the cell bodies of anterior horn motor neurons was assessed semiquantitatively using a 4-point scale (zero = staining absent, + = weak, ++ = moderate, +++ = strong). For the neuropil staining, immunoreactivity was considered weak if it was poorly apparent at low-power magnification, but staining could be identified using the highpower objective. Moderate and strong staining reactions were apparent at low power. Heterogeneity of staining in anterior horn motor neurons was determined for VEGF (Biogenex antibody) and VEGFR2 in spinal cord at the cervical cord level and assessed semiquantitatively. An eyepiece grid was used with a 403 objective (to give a field area of 0.1024 mm 2 ) and 5 fields assessed for both left and right anterior horn, covering representative areas of the central, anterior, posterior, left, and right areas of each anterior horn. Each neuron within each field was assessed semiquantitatively for strength of staining using the 4-point scale (excluding areas of lipofuscin that displace staining). The numbers of neurons in each staining category were then converted to proportions to control for variation in absolute numbers of neurons represented. For statistical analysis, groups were combined to allow the relative assessment of the proportions of neurons showing weak (zero or +) versus strong (++ or +++) staining.
Image analysis was performed, blind to case type and semiquantitative results, on sections from the cervical cord to quantify staining in anterior and posterior horn neuropil for VEGFR2, SNAP25, and synaptophysin. Quantitative analysis of staining was obtained using a digital image acquisition system comprising a microscope (Zeiss Axioplan F2) coupled to a high-sensitivity JVC-CCD color video camera and a Diamondtron NF desktop microcomputer with distortion-free, flat-faced desktop monitor (1,000 3 1,200 [UXGA] pixels spatial resolution) For each measurement, 3 fields were captured from the right and left side using a 0.63ÕCÕ mount and stored as JPEG files. Fields were randomly chosen from the area of interest and obtained with a 203 lens. The slides were illuminated with a stabilized halogen light source at a constant voltage. Images were acquired at 512 3 512 pixels (RBG mode) allowing sufficient resolution for optimal color analysis. The images were analyzed with Image Pro Plus software (Media Cybernetics, Silver Spring, MD). A partially automated procedure was used to compute the proportion of field stained with the appropriate antibody. Blood vessels and large neurons were excluded from the region of interest. The mean value of 6 fields from left and right sides was used in the statistical analysis.
Statistics
Statistical comparisons of staining were performed on results from the cervical level (staining was similar at lumbar levels). For statistical comparisons of staining intensity, cases were grouped into those with low (zero or +) and those with high (++ or +++) staining and comparisons made using the Fisher exact test. The Mann-Whitney U test was used to compare the proportions of neurons showing weak expression in control versus ALS groups, and a t-test was used to compare the proportional areas of neuropil staining as determined by image analysis. Results were considered significant at p , 0.05. Statistical analyses were performed using SPSS (Statistical Package for the Social Science) version 10.1.
Western Blotting
Anterior horns were dissected from 2-mm transverse sections of frozen human spinal cord and homogenized in 10 mL per mg tissue homogenization buffer (25 mM Tris-HCl, pH7.4, 1% v/v Triton 3 100, 100 mM EDTA, 1% w/v sodium deoxycholate, 100 mM TLCK, 2 mg/mL leupeptin A, 1 mM pepstatin, 0.1 mM PMSF, 0.1 mM sodium orthovanadate). Samples were sonicated at 6 mm for 30 seconds and then spun at 800 g for 10 minutes. The protein concentration in the 
Quantitative Reverse Transcriptase-Polymerase Chain Reaction
Five hundred to 800 lower motor neurons from 3 ALS cases and 2 controls were isolated from 10-mm sections of cervical cord and stained with toluidine blue using the Acturus Pixcell laser capture microdissector. RNA was extracted using the Picopure kit (Ambion, Huntingdon, U.K.) and amplified in 2 rounds of linear amplification using the Picoamp kit (Ambion) according to the manufacturer's instructions. cDNA was synthesized from DNAseI (Invitrogen)-treated amplified RNA using random hexamers (Amersham Biosciences) and Superscript II (Invitrogen) according to the manufacturer's instructions. Quantitative PCR was carried out on this cDNA using SYBRgreen and primers for Actin (forward TCCCC-CAACTTGAGATGTATGAAG, reverse AACTGGTCTCAA-GTCAGTGTACAGG) and VEGFR2 (forward ACCCTCAT-ATCTGTCCTGATGTGATAT, reverse TTGAACCTCCCG-CATTCAGT). Primers were designed to cross intron/exon boundaries to minimize genomic DNA amplification. PCR reactions contained 1 mL cDNA, 10 mL SYBR green (Applied Biosystems, Warrington, U.K.), forward and reverse primers at 900 nM for VEGFR2 primers, and 75 nM for actin primers in a total volume of 20 mL. After an initial denaturation of 95°C for 10 minutes, products were amplified by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute on an MX3000P realtime PCR System (Stratagene, La Jolla, CA).
RESULTS
Immunohistochemistry VEGF
Immunohistochemistry using 2 different antibodies to VEGF (Zymed and Biogenex) demonstrated similar staining patterns. Control and motor neuron disease cases showed similar immunoreactivity, and no significant difference was noted between cervical and lumbar regions of the spinal cord. Cord grey matter showed a finely punctate staining pattern in both posterior and anterior horns. This resembled the staining pattern with the synaptic markers SNAP25 and synaptophysin. In some cases, finely granular staining was seen on the surface of anterior horn cells and on the surface of major neurites, raising the possibility of synaptic labeling. In 2 ALS cases, these labeled structures appeared larger and more prominent (Fig. 1A, B) . VEGF was expressed diffusely in the soma of anterior horn cells (and other neurons) with extension of expression into neurites. This was demonstrated particularly with the Biogenex antibody. A greater proportion of neurons showed low expression of VEGF in the ALS compared with the control cases (p = 0.006, Fig. 2 ). In 2 of the ALS cases, densely staining areas of VEGF were seen in the anterior horn cell cytoplasm in structures with the morphology of compact inclusions (Fig. 1C) . In the white matter of the cord, axonal profiles in cross section showed expression of VEGF. The Biogenex antibody also showed some expression in cytoplasm of reactive astrocytes in several of the ALS cases.
Immunostaining in tissue from frontal association cortex was generally weaker than seen in corresponding spinal cord. Staining in cortical structures was strongest in pyramidal neurons, which showed somatic staining with extension into apical neurites. In some cases, positively stained bundles of neurites could be seen running perpendicular to the cortex. Granular staining on the surface of cells was not conspicuous. The neuropil of the cortex demonstrated a weak, finely granular staining pattern. Weak staining was seen in white matter axons in some cases. Normal glia did not demonstrate expression of VEGF, but expression was seen in the cytoplasm of reactive astrocytes in white matter in 3 cases (Fig. 1D) .
VEGFR2
Appearances were similar in both cervical and lumbar spinal cord regions. Strong expression of VEGR2 was observed in the cell bodies of anterior horn motor neurons and in their neurites (Fig. 3) . In comparison to control cases, ALS cases tended to show more variable expression in the somata of motor neurons and a greater proportion of anterior horn motor neurons showed low staining (p = 0.009; Table 3 ). Staining also appeared to be displaced by lipofuscin. In ALS cases in which compact ubiquitinated inclusions were present, serial section preparations with VEGFR2 antibody did not stain these inclusions (Fig. 3E, F) .
The spinal cord grey matter showed a punctate granular staining pattern in both posterior and anterior horns. This pattern of staining was similar to the pattern obtained with the synaptic markers SNAP25 and synatophysin. Granular surface reactivity on the surface of neurons was seen in a few cases, resembling synaptic structures. These were less conspicuous than observed for VEGF. Where present, however, they had a very similar distribution to boutons stained with SNAP25 on serial sections, suggesting that they colocalized with them, supporting the interpretation that they represent synaptic structures (Fig. 3C, D) . Image analysis showed that the area of staining of the neuropil was also reduced in ALS cases in the anterior horns compared with controls (p = 0.018; Table 3 , Fig. 4A ), and staining in anterior horns tended to be less than in the substantia gelatinosa. SNAP25 and synaptophysin both produced a granular synaptic pattern of staining of the anterior horn neuropil (Fig. 5) . These antibodies also variably stained motor neuron perikarya and stained synaptic boutons on the surface of the cells. This pattern was thus similar to that obtained with VEGF and VEGFR2. Neuropil staining for synaptophysin was reduced in ALS cases (p = 0.004). The reduced VEGFR2 staining thus showed a similar pattern of reduction to that of synaptophysin. However, in contrast, neuropil expression of SNAP25 remained strong in both ALS and control cases (Table 3 ; Fig. 4B) .
A thin rim of cytoplasmic positivity for VEGFR2 was observed in some glia in white matter. Staining was observed on the endothelium of capillaries and on smooth muscle of leptomeningeal small arteries. Some reactive glia in the lateral corticospinal tracts of ALS cases showed greater staining (reflecting the increased cytoplasmic area), with some extension into processes, but not all reactive cells showed staining, and macrophages did not stain. There was strong expression of VEGFR2 in the hippocampus, including neurons, glia, and blood vessels (data not shown). Expression was also noted in ependyma, choroid plexus, and weak staining of neuropil was seen. Staining was similar in controls and ALS cases. VEGFR2 staining was weaker in the frontal cortex than in the spinal cord. Moderate staining of pyramidal cells and other neurons was noted with weak staining of cortical neuropil. Weak endothelial and white matter glial staining was noted in some cases. There was no apparent difference between ALS and control cases in the pattern or intensity of staining observed in the hippocampus and frontal cortex.
Neuropilin-1
Strong expression of NRP1 was observed in leptomeningeal blood vessels around spinal cord (Fig. 6A) . Staining was strong in both smooth muscle and in endothelium. In contrast, only weak staining was observed in parenchymal blood vessels, where it tended to be stronger in larger vessels with smooth muscle. Weak or an absent staining reaction was observed in anterior horn cells and neuropil in most cases, although moderate or strong staining was seen in some cases (Fig. 6B) . One ALS case showed prominent staining of varicosities on the surface of anterior horn cells (Fig. 6C ), but these features were less conspicuous than with antibodies to VEGF or VEGFR2. No inclusions labeled for NRP1. NRP1 expression was seen in reactive glial cells with process formation (Fig. 6D) . NRP1-expressing glial cells were observed in more ALS than control cases (80% of ALS compared with 20% of controls, p = 0.005), reflecting the increased white matter gliosis seen in long tracts in ALS. With the exception of changes related to gliosis, little difference was noted between ALS and control cases. Staining for NRP1 was generally weaker in the frontal cortex than in the spinal cord. It was observed in leptomeningeal vessels, but only in occasional parenchymal vessels in white matter. Weak staining was seen in pyramidal neurons and also in reactive glia in white matter when present. In the hippocampus, weak staining was seen in leptomeningeal vessels. Expression was observed in reactive glia in a control case.
Western Blotting
In Western blots of protein extracts from ventral horn tissue using VEGF antibody, a 48-kd VEGF band was visualized. This band was weak in one patient with ALS and one control case, which is partly accounted for by differential protein loading (Fig. 7) . No significant difference was seen in the level of VEGF expression between patients with ALS and controls (Table 4) . Quantitative Reverse Transcriptase-Polymerase Chain Reaction VEGFR2 transcripts were present in motor neurons isolated by laser capture from the spinal ventral horn. Levels of VEGFR2 expression correlated with semiquantitative analysis of VEGFR2 expression by immunochemistry ( Fig. 8 ; Table 5 ), although numbers were too small for statistical analysis.
DISCUSSION
We have shown by immunochemistry that both VEGF and its receptor VEGFR2 are expressed by lower motor neurons in the spinal cord and by upper motor neurons in the cerebral cortex. Immunoreactivity to VEGF and VEGFR2 was seen in neuronal somata, neurites, and in axonal profiles, and production of VEGFR2 mRNA in motor neuronal somata was confirmed by quantitative RT-PCR (QPCR). Image analysis of neuropil staining of VEGFR2 confirmed that expression of VEGFR2 in the neuropil is reduced in patients with ALS compared with control cases. Semiquantitative analysis of the immunohistochemical findings showed a significantly greater proportion of neurons expressing low levels of both VEGF and VEGFR2 in patients with ALS than in control spinal cord. This finding was confirmed for VEGFR2 by QPCR: the level of expression of VEGFR2 message determined by QPCR correlated with protein levels seen on immunohistochemical analysis. The similar distributions of expression of VEGF and its receptor would suggest an autocrine or paracrine mode of action of VEGF released by motor neurons. Furthermore, our finding that expression of VEGF and its major agonist receptor are downregulated in anterior horn cells (AHCs) and neuropil of the spinal cord supports the hypothesis that dysregulation of the VEGF signaling pathway has a role in the pathogenesis of motor neuron degeneration in ALS.
Expression of VEGF and its receptors has been demonstrated on neurones in the adult rodent central nervous system, including motor neurones (12, (16) (17) (18) . Two previous studies have described the expression of VEGF and its receptors in the adult human central nervous system. A study of postmortem brain tissue from patients experiencing an acute stroke detected VEGF protein by Western blotting in the normal brain. Using immunochemistry, both VEGF and VEGFR2 were undetectable in neurons and glial cells of the normal hemisphere, but VEGF was present in neurons and reactive glia and VEGFR2 in endothelial cells in the stroke penumbra (19) . An immunohistochemical study of the expression of VEGF receptors in ALS spinal cord reported that in control cases, VEGFR2 expression was not detected, VEGFR1 was expressed on blood vessels, and there was diffuse VEGFR3 staining throughout the neuropil. In ALS cases, VEGFR1 was expressed on reactive astrocytes, VEGFR2 at low levels on glia and blood vessels, and VEGFR3 expression in the neuropil declined with neuronal loss. The expression of VEGF or neuropilin were not discussed (20) . Our findings differ from these studies in that we saw strong expression of VEGFR2 on AHCs and neuropil of the spinal cord, and detected weak staining for VEGF and VEGFR2 in cortical neurons and in the normal brain. We confirmed the veracity of VEGFR2 expression in spinal motor neurons at mRNA level using QPCR. The veracity of VEGF immunostaining was confirmed with a second antibody, which gave very similar results and by carrying out Western blotting of punched ventral horn with a third antibody (R&D Systems) to confirm expression. Immunoblotting would ideally have been carried out with the same antibodies as the immunohistochemistry work. However, these antibodies were not sufficiently sensitive in Western blot analysis, whereas the R&D Systems antibody gave poor results on immunohistochemical studies of paraffinembedded tissue. The quantitative difference in expression of VEGF by motor neurons in cases versus controls was not confirmed by Western blotting. However, because whole ventral horn extracts were used for immunoblotting, a difference in VEGF expression levels in the minority population of motor neurons would be masked by the presence of other cell types. Unlike its receptor, differences in VEGF expression were not demonstrated by immunochemistry in the background neuropil. VEGF has a trophic effect on motor neurons in in vitro models of cellular stress mediated by VEGFR2 and neuropilin and the PI3K/Akt pathway (12, 21) . In a mouse model of spinal cord ischemia, intraperitoneal administration of VEGF reduces paralysis, whereas VEGF d/d mice are severely paralyzed by a mild ischemic insult (13) . Neuronal overexpression of VEGFR2 delays disease onset in the SOD1 G93A mouse model of ALS (22) , and VEGF delays both onset of disease and death when delivered to SOD1 G93A transgenic rodents by intramuscular injection of a retrogradely transported viral vector (23) or by intraventricular delivery (22) . In a mouse model of spinobulbar muscular atrophy, expression of mutant human androgen receptor downregulates CBPmediated transcription of VEGF (24) . In cell and animal models, VEGF has a functional effect on motor neuron survival, and reduction of VEGF expression causes motor neuron death. No mutations in the VEGF gene are described in patients with ALS. However, 2 haplotypes of functional promoter region polymorphisms, which are associated with reduced VEGF expression, conferred a 1.8-fold increased risk of ALS in a large European association study (13) . Lower levels of VEGF have been demonstrated in the cerebrospinal fluid of patients with ALS compared with controls (25) . Our finding of a reduction in motor neuronal expression of VEGF and VEGFR2 and of reduced expression of VEGFR2 in the neuropil adds to the body of evidence of downregulation of VEGF signaling pathways in ALS.
Expression of VEGF and VEGFR2 was seen in a punctate distribution in the grey matter in a pattern similar to that of the synaptic markers synaptophysin and SNAP25, suggesting that VEGF and its main agonist receptor may also have a synaptic localization. The punctate staining on the surface of motor neurons and proximal neurites, in some cases quite coarse, suggested localization to synaptic structures, although this subcellular localization was not proven. The reduction in VEGFR2 expression in the neuropil, quantified by image analysis, parallels a reduction in synaptophysin expression. Synaptophysin is located in the membranes of synaptic vesicles and has an uncertain role. It has previously been shown that synaptophysin is reduced in cerebral cortex and spinal cord of patients with ALS, originally thought to reflect loss of presynaptic terminals (26) . However, in contrast to VEGFR2 and synaptophysin, SNAP25, which marks a different component of the synapse, was not reduced in the ALS cases. SNAP25 is located on the presynaptic membrane and is one of the SNARE complex of proteins comprising SNAP25, VAMP2, and syntaxin I, which mediates fusion of synaptic vesicles (27) . The significance of synaptic vesicle proteins to motor neuron survival has recently been highlighted by the identification of a missense mutation in the VAMP-associated protein B (VAPB) gene in 7 kindreds with motor neuron diseases (6) . Synaptic vesicle-related proteins and presynaptic membrane proteins appear to be differentially FIGURE 7 . Western blot of protein extracts from ventral horn tissue using VEGF antibody mab293 or actin antibody ab8227 as a loading control under nonreducing conditions. In 2 patients and 2 controls, a 48-kd VEGF band was visualized. Numbers in bold refer to case numbers given in Table 1 . affected in neurodegeneration. Preferential loss of synaptophysin and relative preservation of SNAP25 has been shown in Alzheimer disease (28) and in the neuropil of the spinal cord in ALS (29) . This suggests that rather than simple synaptic loss in ALS, the reduction in synaptophysin and VEGFR2 expression may reflect preferential downregulation of a subset of synaptic proteins or selective degeneration of certain synaptic components. The VEGF coreceptor, neuropilin, showed a different expression pattern, which was relatively weaker in neuronal components compared with vessels. The expression of VEGF, neuropilin and, to a lesser extent, VEGFR2 on reactive glia in ALS suggests a possible role as a driver of gliosis, which is a characteristic pathologic feature of this disease. Expression of VEGF by reactive astrocytes is a common feature of several models of central nervous system injury (30, 31) , and VEGF has a mitogenic effect on astrocytes in vitro (32) . In 2 ALS cases, structures resembling inclusions that stained strongly positive for VEGF were seen within AHCs. Although we report this as an interesting staining pattern, we have no further evidence that these are VEGF-containing compact inclusions. On serial sections, ubiquitinated inclusions excluded VEGFR2 staining. We observed VEGFR2 and NRP1 staining of endothelial cells and smooth muscle of blood vessels. NRP1 staining was observed predominantly in larger leptomeningeal blood vessels, whereas VEGFR2 was expressed more strongly in capillary endothelium. The vascular distribution of these receptors is in keeping with their role in mediating hypoxic vascular responses (9) .
In conclusion, there is growing evidence that VEGF is an important determinant of motor neuron survival. We have shown that VEGF and its major agonist receptor, VEGFR2, are expressed in neurons of adult human brain and spinal cord, consistent with autocrine/paracrine actions of this neurotrophic factor, and in a pattern that suggests synaptic localization. Significant reductions in expression of VEGF and VEGFR2 are seen on motor neurons in the spinal cord of patients with ALS, supporting the hypothesis that a reduction in its neurotrophic effect may play a role in the etiology of ALS. Maintenance of SNAP25 expression in neuropil of the ALS spinal cord suggests preservation of synaptic structures, whereas parallel reduction in VEGFR2 and synaptophysin expression may reflect downregulation of a subset of synaptic proteins in ALS. Table 1 .
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